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etinopathy and the association with pegylated interferon and
ibavirin
. Farley ∗, A. Truong, T. Nguyen, W. Shum
Dr John Farley Inc, Vancouver, BC, Canada
Background: Treatment of hepatitis C (HCV) with Pegylated
nterferon and Ribavirin can result in a many adverse effects
ut ocular complications are considered rare, benign and usually
eversible which does not require the cessation of treatment regi-
en. It has been suggested that retinopathy in patients undergoing
reatment with Pegylated interferon are increase if a history of
ypertension is present. However, retinopathy can occur without
istory of hypertension.
Methods: Retrospective chart review of 4 individuals who
eveloped retinal complications during hepatitis C treatment with
egylated Interferon Alfa 2a and Ribavirin.
Results: 4 Males, average age 49.75±5.97 years. Ethnicities: 2
aucasian, 1 Vietnamese, 1 Aboriginal. We assessed for other co-
orbidities such as diabetes (1 was uncertain); hypertension, and
ypercholestrol were not a factor. 2 was genotype 2, 1 genotype 3,
nd 1 genotype 1. Rapid viral response with HCV RNA undetected
t week 4 was noted for 3 with genotype 2 or 3, and early viral
esponse with HCV RNA undetected at week 12 was noted for 1
ho had genotype 1. Fibrosis: 1 No Fibrosis, 1 Fibrosis Stage 2, 1
ibrosis Stage 3, and 1 did not complete a biopsy. Averages wait
ime from likely infected date to treatment 20 years. Average wait
ime from year diagnosed was 6.67 years. 2 likely acquired through
ntravenous drug use and 2were uncertainwho they acquiredHCV.
etinal complications occurred between weeks 14 and 26 of treat-
ent with average time of 21 weeks into treatment. Diagnoses
ntertained included blurry vision in both eyes to retinal hemor-
hage and atherosclerotic retinopathy.
Conclusion: Retinopathy in patients treated with Pegylated
nterferon Alfa 2a and Ribavirin is considered rare. However, rou-
ine follow up is essential for management on treatment. We
peculate that individuals with more severe disease may be more
ikely to develop retinopathy. More research should be completed
norder toevaluate this aspect.Multidisciplinarymanagementdur-
ng the course of treatment is essential towards identifying and
onitoring for side effects and treatment response.
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Hepatitis C treatment outcome with pegylated interferon alpha
2a/ribavirin in a real life Community-based setting
J. Farley ∗, A. Truong, T. Nguyen, W. Shum
Dr John Farley Inc, Vancouver, BC, Canada
Background:Hepatitis C virus (HCV) can be successfully treated
with Pegylated Interferon Alpha 2a and weight-based Ribavirin for
a duration of 24 or 48 weeks depending on the genotype. The
likelihood of response is determined by virological factors such
as genotypes, viral load, and host factors such as degree of liver
ﬁbrosis, ethnicity. This study based on real-life setting validates
published studies (usually based in tertiary-care/ academic insti-
tution settings) on the feasibility and efﬁcacy of treating HCV in
diverse community-based clinical populations.
Methods: Medical chart review of 389 patients who under-
went HCV therapy between January 2001 and September 2011
in a community-based clinical setting in British Columbia. Treat-
ment is based on current standard of care recommendations using
Pegylated intrferon alpha 2a and Ribavirin combination. However,
Ribavirin dose was usually higher than recommended in at least
50% of cases. Laboratory tests (requested but not necessarily done
by all patients): HCV RNA at weeks 0, 4, 12, 24, 48 (Non-Genotype
2 & 3) and 6 months post treatment completion. Deﬁnitions:
Rapid virological response (RVR) is achieved when HCV RNA is not
detected at week 4, early virological response (EVR) at week 12
of treatment and sustained virological response (SVR) at least 6
months after completion of treatment.
Results: Per protocol, 45 were discontinued: “adverse side
effects” (7): Myocardial Infarction (1), surgery (2). Two deceased.
Null response after week 12 (33), voluntary discontinuation due to
other reasons (1).
56 patients were excluded from SVR analysis: lost to follow up
(31), pending SVR (19), still on treatment (1), missing data (5).
76.6% (259/333) achieved SVR: genotype 1; 72.0% (126/175),
genotype 2; 89.7% (35/39), genotype 3; 82.6% (95/115), genotype
other; 75.0% (3/4). Of thosewith RVR determinations 92.8% (90/97)
achieved SVR, and with EVR 89.4% (193/216) had SVR.
GENOTYPE BY TREATMENT RESPONSE
GENOTYPE (N) RVR NO RVR EVR NO EVR ETR NO ETR SVR NO SVR
1 (175) 28 (19%) 119 99
(57.6%)
73 139
(79.9%)
35 126 (72%)49
2 (39) 19
(54.3%)
16 32
(82.1%)
7 36
(92.3%)
3 35
(89.7%)
4
3 (115) 49
(53.8%)
42 81
(77.1%)
24 109
(94.8%)
6 95
(82.6%)
20
OTHER (4) 1 (25%) 3 4 (100%) 0 4 (100%) 0 3 (75%) 1
Total 97 180 216 104 288 44 259 74
Fisher Exact P-Value 0.000 0.0003 0.001 0.033
SVR BY EARLY VIRAL
RESPONSE
RVR NO RVR EVR NO EVR
SVR 90
(92.8%)
123 193
(89.4%)
55
NO SVR 7 57
(31.7%)
23 49
(47.1%)
Fisher Exact P-Value 0.00 0.00
SVR BY RIBAVIRIN DOSE
MISSING <=1 1-1.5 >1.5
SVR 40
(75.5%)
69
(67.6%)
135
(84.4%)
15
(83.3%)
NO SVR 13 33 25 3
Fisher Exact P=0.006
Missing column was excluded for statistically analysis. Fisher Test, P=0.006. Overall
the effectiveness of Ribavirin dosage on SVR was statistically signiﬁcant predictor
of SVR.
